marked.bio

Company

I-Mab Biopharma US

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

nivolumab 2durvalumab 1

Trials

2 of 2 trials shown

  1. Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

    Recruiting Phase 2 I-Mab Biopharma US Started 2026Primary completion 2030-03 NCT07432295

    Givastomignivolumabfluorouracilleucovorinoxaliplatincapecitabine

    CLDN18.2 positive (membrane intensity score ≥1+ on ≥1% of tumor cells).

    Claudin 18.2 expressionSolid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer

  2. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 I-Mab Biopharma US Started 2021Primary completion 2026-12 NCT04900818

    TJ033721 (givastomig)nivolumabTJ033721 (givastomig), chemotherapydurvalumab

    Must have CLDN18.2-positive tumor expression

    Claudin 18.2 expressionSolid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer